[Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
Fibrinogen degradation products could be detected frequently in patients with metastasized tumour disease. Plasminogen, antithrombin III and fibrinogen were not found to be elevated. The proteinase inhibitors alpha 2-macroglobulin, alpha 1-antitrypsin and C1-esterase inactivator were measured before and after chemotherapy. alpha 1-antitrypsin and C1-esterase inactivator were elevated in patients with pulmonary and/or retroperitoneal metastases. Regardless of the stage of the tumour disease serum level of alpha 1-antitrypsin and C1-esterase inactivator in increased under cytotoxic chemotherapy.
D000933:Antifibrinolytic Agents / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000990:Antithrombin III / Q000378:metabolism; D003174:Complement C1 Inactivator Proteins / Q000097:blood; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000097:blood; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D010958:Plasminogen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000097:blood; D012208:Rhabdomyosarcoma / Q000097:blood; D013736:Testicular Neoplasms / Q000097:blood; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000378:metabolism
D000933:Antifibrinolytic Agents; D000970:Antineoplastic Agents; D003174:Complement C1 Inactivator Proteins; D005338:Fibrin Fibrinogen Degradation Products; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen
Fibrinolyse-Inhibitoren und Fibrinogenspaltprodukte bei Patienten mit malignen Erkrankugen.